Inhalation Sciences receives new order worth 292 KEUR from Aquilon Pharma

(Stockholm, 18 December 2020) Innovative inhalation pharmaceutical technology company Aquilon Pharma, based in Belgium, has signed a purchase order for ISAB’s high-precision R&D system PreciseInhale®, plus its Nose-Only and Intratracheal Exposure Modules. The combined value of the order is 292 KEUR.

Aquilon Pharma, originally founded as a spinout from the University of Liège, Belgium, has an innovative portfolio of new formulations that significantly improves the efficacy of inhaled drugs for asthma and COPD (Chronic Pulmonary Obstructive disorder). Strongly focused on precision and quality, the company’s dry powder and nebulized formulations can also be used in developing existing non-inhaled drugs as inhalable.

Aquilon Pharma has ordered PreciseInhale®, ISAB’s high-precision aerosol R&D system, plus its Nose-Only and the unique Intratracheal Exposure Modules. The total order is worth 292 KEUR.

ISAB CEO Manoush Masarrat: “We are pleased to welcome a fellow pioneer in next-generation inhalation technology as new customer. We know how deeply Aquilon Pharma value precision and efficacy as key drivers for better treatment and care for patients, and we’re proud that PreciseInhale® will be playing an important role in helping them achieve that.”

Aquilon Pharma CEO Paul MAES: “Aquilon is happy to acquire the PreciseInhale® equipment. It will be a great opportunity to work, together with highly experienced colleagues from the University, on innovative respiratory medicine research. Through this unique technology we will be able to move forward and extend the portfolio of our products in development. Aquilon intends to address all the challenges existing in the field of lung disease treatments and proposes drug products that are environment-friendly, easy to use and which allow a better lung deposition. Aquilon will carry out three clinical studies in 2021 to finalize its research. The company is today launching a 20 MEURO fund-raising campaign to finance its pre-commercialization projects."

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for aerosol generation and inhalation research. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.  

The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on December 18, 2020 at 0945 CET.

Tags: